RxDoctor Payments Data

Marc Chapman, MD

Internal Medicine · Euless, TXNPI 1679578777

Payments from drug & device makers

$3,125in general payments, 2019–2025

Across 177 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$656
  • GSK$393
  • Abbott$259
  • Novo Nordisk$165
  • Astellas Pharma US Inc$158
  • Novartis$129
  • plus $1K from 35 others

What the payments were for

  • Food & beverage$3,125100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,125 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$107,373
Medicare patients
301
Services billed
1,849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban153$141,848
OzempicSemaglutide88$116,585
JardianceEmpagliflozin87$90,078
XareltoRivaroxaban54$49,685
FarxigaDapagliflozin Propanediol33$38,789
TrulicityDulaglutide38$37,675
MounjaroTirzepatide27$29,966
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$27,720
JanuviaSitagliptin Phosphate16$21,188
Combivent RespimatIpratropium/Albuterol Sulfate24$13,772
LinzessLinaclotide15$11,003
MyrbetriqMirabegron11$10,428
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$9,815
EntrestoSacubitril/Valsartan12$8,371
Atorvastatin Calcium878$6,906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$48$144,642194 claims
Novo NordiskOzempic, Levemir$165$121,538107 claims
Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat, Stiolto Respimat$113$115,223134 claims
Lilly USA, LLCTrulicity, Mounjaro$123$67,64165 claims
Johnson & JohnsonXarelto$78$49,68554 claims
AstraZenecaFarxiga$77$38,78933 claims
GSKTrelegy Ellipta$393$27,72034 claims
MerckJanuvia$13$21,18816 claims
AbbVieLinzess, Synthroid$656$13,67851 claims
Astellas Pharma US IncMyrbetriq$158$10,42811 claims
NovartisEntresto$129$8,37112 claims
Sanofi-aventis U.S. LLCLantus$12$2,05026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Euless

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →